Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Carcinoma, Renal Cell 63Carcinoma, Hepatocellular 25Prostatic Neoplasms 21Neoplasm Metastasis 19Neoplasms 17Carcinoma, Non-Small-Cell Lung 16Kidney Neoplasms 14Osteosarcoma 9Neuroendocrine Tumors 9Carcinoma, Transitional Cell 9Sarcoma 8Colorectal Neoplasms 8Carcinoma, Medullary 8Urinary Bladder Neoplasms 7Sarcoma, Ewing 7Melanoma 7Breast Neoplasms 7Brain Neoplasms 7Thyroid Neoplasms 6Ovarian Neoplasms 6Clear-cell metastatic renal cell carcinoma 6Recurrence 5Pancreatic Neoplasms 5Lung Neoplasms 5Carcinoma 5Urethral Neoplasms 4Triple Negative Breast Neoplasms 4Multiple Myeloma 4Thyroid Cancer, Papillary 3Small Cell Lung Carcinoma 3

Interventions

tofacitinib 7Etanercept 6Methotrexate 3Adalimumab 3secukinumab 2Nivolumab 2sotrastaurin 1sodium luminolate 1ixekizumab 1deucravacitinib 1calcipotriene 1cabozantinib 1baricitinib 1apremilast 1abrocitinib 1Vitamin D 1Vaccines 1Specimen Handling 1Saline Solution 1Platinum Compounds 1Ipilimumab 1Herpes Zoster Vaccine 1Folic Acid 1Fish Oils 1Fatty Acids, Omega-3 1Exercise 1Eicosapentaenoic Acid 1Docosahexaenoic Acids 1Cholecalciferol 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Psoriasis × cabozantinib × Clear all
NCT03816345 2026-05-13

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

National Cancer Institute (NCI)

Phase 1 Recruiting
300 enrolled
Other hematologic neoplasm

Arthritis, Rheumatoid, Autoimmune Diseases, Colitis, Ulcerative, Crohn Disease, Dermatomyositis, Lupus Erythematosus, Systemic, Multiple Sclerosis, Psoriasis, Scleroderma, Systemic, Sjogren's Syndrome, Inflammatory Bowel Diseases, Arthritis, Psoriatic, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡